ARNA Volume Alert - ARNA 4.33 Arena Pharmaceuticals $ARNA

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 2:45 PM

ARNA Volume Alert - ARNA 4.33 Arena Pharmaceuticals $ARNA Hit a high of 4.38 Currently 11:15 Last price 4.33 +0.07 +1.64% With a day low of 4.22 and a current volume of 1,814,776.

ARNA Arena Pharmaceuticals Recent Headline News

Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - 1 hr 20 mins ago

OREX: 5.11 (+1.26), VVUS: 3.23 (-0.10), ARNA: 4.34 (+0.08)

Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.11 (+1.26), VVUS: 3.23 (-0.10), ARNA: 4.34 (+0.08)

Belviq Sales Dip Slightly - Quarter Is Flat Thus Far
Spencer Osborne - at Seeking Alpha - Fri Nov 07, 12:02PM CST

VVUS: 3.23 (-0.10), ARNA: 4.34 (+0.08)

Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST

OREX: 5.11 (+1.26), VVUS: 3.23 (-0.10), ARNA: 4.34 (+0.08)

Will Belviq Advertising Pick Up Again?
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:55AM CST

VVUS: 3.23 (-0.10), ARNA: 4.34 (+0.08)

Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases
PR Newswire - Thu Nov 06, 7:00AM CST
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 7-11, 2014, in Boston, Massachusetts.
ARNA: 4.34 (+0.08)

Arena Pharmaceuticals to Present at Credit Suisse 2014 Healthcare Conference
PR Newswire - Wed Nov 05, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014, at 3:00 p.m. Mountain Time (5:00 p.m. Eastern Time), at The Arizona Biltmore in Phoenix, Arizona.
ARNA: 4.34 (+0.08)

Arena Pharmaceuticals Posts In Line Q3 Loss, Belviq Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 8:30AM CST
Arena Pharmaceuticals (ARNA) reported a net loss of 13 cents per share in the third quarter of 2014 in line with the Zacks Consensus Estimate.
VVUS: 3.23 (-0.10), AMAG: 34.75 (-0.20), ARNA: 4.34 (+0.08)

Orexigen's Contrave Has Modest Start
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:30PM CST

OREX: 5.11 (+1.26), ARNA: 4.34 (+0.08)

Arena Beats The Street On Taigen Stock Sale
Spencer Osborne - at Seeking Alpha - Mon Nov 03, 12:26PM CST

ARNA: 4.34 (+0.08)

Arena Pharmaceuticals' (ARNA) CEO Jack Lief on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 11:53AM CST

ARNA: 4.34 (+0.08)

Arena Pharmaceuticals (ARNA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 03, 7:25AM CST

ARNA: 4.34 (+0.08)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 107.29 (+0.84), CLVS: 59.13 (+0.82), ARWR: 6.24 (+0.18), ACHN: 12.56 (+2.45), MRK: 58.80 (-0.54), RTRX: 10.52 (+0.14), RGLS: 21.41 (-0.67), EPZM: 23.61 (-0.14), AGIO: 79.67 (+7.61), RMTI: 10.60 (+0.05), ARNA: 4.34 (+0.08), KERX: 16.38 (-0.35)

Arena product revenues up 185%
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 6:36AM CST

ARNA: 4.34 (+0.08)

Arena Pharmaceuticals tops 3Q profit forecasts
Automated Insights - Mon Nov 03, 6:27AM CST
SAN DIEGO (AP) _ Arena Pharmaceuticals Inc. (ARNA) on Monday reported a third-quarter loss of $10.7 million.
ARNA: 4.34 (+0.08)

Arena Pharmaceuticals beats by $0.07, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 5:56AM CST

ARNA: 4.34 (+0.08)

Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 03, 5:45AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2014.
ARNA: 4.34 (+0.08)

Eisai and Arena Pharmaceuticals Report Results of an Investigational Phase 2 Trial of Lorcaserin HCl as an Aid for Smoking Cessation
PR Newswire - Mon Nov 03, 5:30AM CST
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced top-line results from the Phase 2 trial investigating lorcaserin HCl, a serotonin 2C receptor agonist, for smoking cessation. The trial demonstrated statistically significant improvement over placebo in reducing the number of patients who smoke after 12 weeks of treatment. The detailed results of the trial are expected to be presented at a future scientific meeting.
ARNA: 4.34 (+0.08)

Notable earnings before Monday’s open
Seeking Alpha - at Seeking Alpha - Sun Nov 02, 4:30PM CST

ACW: 4.90 (-0.05), SYY: 38.49 (+0.35), L: 43.26 (-0.25), EEP: 35.72 (-0.21), SNH: 22.34 (+0.06), INN: 11.67 (unch), ITG: 19.68 (-0.11), NSP: 33.53 (-0.41), S: 4.86 (+0.14), ALE: 52.35 (+0.10), GVA: 36.30 (-0.06), MCY: 55.28 (+0.35), ARNA: 4.34 (+0.08), CHD: 73.45 (+0.18), ARE: 83.70 (+1.32), USAK: 17.45 (-0.02), BWP: 17.05 (+0.03), KRG: 26.80 (+0.04), CYOU: 23.58 (+1.17), MNKD: 5.86 (+0.08), HNT: 47.49 (+0.48), AMH: 17.26 (+0.16), ARCB: 42.59 (+0.19), ANIP: 49.42 (+3.42), AMG: 195.24 (-1.46), HAE: 36.54 (-0.28), SOHU: 51.00 (+0.66), CNA: 39.31 (+0.24)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 4:39PM CDT

FRM: 6.32 (+0.16), TTMI: 6.82 (-0.10), EGO: 5.30 (-0.34), AMBR: 11.17 (-0.23), BDBD: 9.04 (+0.28), DUST: 39.94 (+6.03), BZH: 19.18 (+0.62), ARNA: 4.34 (+0.08), GSAT: 2.64 (+0.02), CTCT: 35.28 (+0.24)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Millrose Faces Class Action: Blame Game in Motion

Millrose Properties: A Realty Ruckus Unfolding Sometimes, in the world of stocks, it feels like you're two steps ahead of the scam or already knee-deep in trouble. Millrose Properties, Inc. struck a rather sour chord recently with an 8.53% stock drop, leaving investors feeling the burn. Here's the juice: a securities fraud class action is in motion, and if you're holding...

Mili and Egnyte Transform Financial Advice Delivery

AI Powers Up Financial Advisors with New Partnership Ah, the grind never ends for those financial advisors, right? Well, here's a nugget that might just lighten their load. Mili and Egnyte are buddying up to merge AI with secure content platforms, aiming to supercharge how advisors handle client documents. Right off the bat, advisors can crank out personalized advice at a...

Hemlo Mining's Q3 2026: Challenges and New Solutions

Resilience in the Face of Operational Setbacks Here's a peek into Hemlo Mining's latest exploits. They're riding a rollercoaster of operational challenges, yet still managing to chug along with stable gold production. It's like trying to drive uphill with a flat tire, but somehow, Hemlo's trucking along without missing too much of a beat. The numbers are in, and despite a...

Dan-O's Seasoning Bags $25M to Spice Up Global Kitchens

Spicing Up The Investment Scene Who would've thought a humble seasoning mix could steal the show in the investment world, eh? Dan-O's Seasoning, that quirky little flavor brand from Louisville, just pulled a $25 million rabbit out of the hat with an investment from The Newcastle Network. That's news worth chewing on. From Farmers Market to Flavor Giant Let's flash back a...

Equity Alerts: Unraveling the Latest M&A Surprises

Diving Into the M&A Controversy On the bustling streets of New York, beneath the towering Empire State Building, a plot unfolds that could shake the foundations of your investments—particularly if you're holding shares in Synaptics, Eagle Financial, Victory Capital, or Centerspace. Juan Monteverde and his legal firepower from Monteverde & Associates PC are launching a...

Minesto Joins Sweden-Indonesia Partnership in Energy Shift

Minesto's Big Splash in Indonesia's Energy Transition Here we go, folks. Minesto's taking the plunge into Indonesia's uncharted tidal waters under a Sweden-backed partnership. This Swedish underdog in ocean energy is ready to shake things up and ride the Indonesian currents, thanks to the Sweden-Indonesia Sustainability Partnership. Now, why should this matter to you, the...

Microencapsulation Market to Hit $24B by 2031

Think about wrapping a tiny gift inside a bubble that's not only protective but also dissolves at just the right moment. That, my friends, is microencapsulation summed up—and it's becoming a big deal. With the market poised to jump from $16.90 billion in 2026 to a whopping $24.02 billion by 2031, at a steady clip of 7.3% annually, there's a lot for investors to chew on...

European Flavors: A Halloween Food Revolution

Who would've thought Halloween would toss a spin on fine dining? What's usually known for candy corn and spooky costumes has teamed up with European flavors for a night unlike any other. And we're talking more than just trick-or-treating here, folks. A New Kind of Halloween Spread This year, The Charming Taste of Europe has thrown itself into the Halloween festivities,...

New American Perspectives Shines at HIFF 2026

Ever notice how the arts can cut through the noise and spotlight voices we often overlook? Well, that's exactly what's happening at the Hawai?i International Film Festival (HIFF) this year. The Vilcek Foundation, alongside HIFF, is bringing the New American Perspectives program back for another round at the festival’s 46th edition, and it's a heck of a lineup....

Highlight's Pulse Offers Real-Time Consumer Insights

Highlight Introduces Pulse for Instant Insights Ever find yourself waiting forever for consumer feedback? Well, folks, Highlight's making sure those days are behind us with their new launch: Pulse. They've taken the conventional consumer testing model and flipped it on its head with Highlight Twins. Imagine getting the pulse of your audience in mere seconds, not the...